[{"id":"nct07414927","name":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following E","tldr":"A phase 1/2 trial in lung cancer, run by Shanghai Best-Link Bioscience, LLC, not yet recruiting.","route":"/trials/nct07414927/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT07414927","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07609251","name":"A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study","tldr":"A phase 2 trial of SCTB41 and docetaxel in lung cancer, run by Sinocelltech Ltd., not yet recruiting.","route":"/trials/nct07609251/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07609251","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05943795","name":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","tldr":"A phase 3 trial of SI-B001 and docetaxel in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active but no longer recruiting.","route":"/trials/nct05943795/","status":"active","kind":"trial","cancerIcon":"lung-squamous-cell-carcinoma","sub":"NCT05943795","facets":{"kind":["Trial"],"cancers":["Squamous cell carcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Squamous cell carcinoma of the lung","href":"/cancers/lung-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06469879","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","tldr":"A phase 3 trial of benmelstobart and anlotinib in lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., not yet recruiting.","route":"/trials/nct06469879/","status":"planned","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT06469879","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06982924","name":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","tldr":"A phase 2 trial of limertinib and bevacizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.","route":"/trials/nct06982924/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06982924","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06931717","name":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re","tldr":"A phase 3 trial of cemiplimab in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","route":"/trials/nct06931717/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06931717","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07133425","name":"A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by M.D. Anderson Cancer Center, now recruiting.","route":"/trials/nct07133425/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07133425","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07710612","name":"A Phase 2 Study of ABSK043 Combined With Osimertinib","tldr":"A phase 2 trial of osimertinib in lung cancer, run by Abbisko Therapeutics Co, Ltd, not yet recruiting.","route":"/trials/nct07710612/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07710612","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01394679","name":"A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Cell>Point LLC, not yet recruiting.","route":"/trials/nct01394679/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT01394679","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07833202","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","tldr":"A phase 3 trial of IN10018, tislelizumab, carboplatin and pemetrexed in lung cancer, run by Shanghai Jeyou Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07833202/","status":"planned","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT07833202","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06177925","name":"A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","tldr":"A phase 2 trial of adebrelimab, carboplatin, cisplatin and etoposide in lung cancer, run by Nanfang Hospital, Southern Medical University, now recruiting.","route":"/trials/nct06177925/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06177925","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07798947","name":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC","tldr":"A phase 2 trial of adebrelimab in lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07798947/","status":"planned","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT07798947","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07283198","name":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, not yet recruiting.","route":"/trials/nct07283198/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07283198","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07824882","name":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","tldr":"A phase 2 trial of adebrelimab in lung cancer, run by Hansoh BioMedical R&D Company, not yet recruiting.","route":"/trials/nct07824882/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07824882","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07815223","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","tldr":"A phase 2 trial of tislelizumab and anlotinib in lung cancer, run by Yantai Yuhuangding Hospital, now recruiting.","route":"/trials/nct07815223/","status":"recruiting","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT07815223","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07318883","name":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab","tldr":"A phase 2/3 trial of serplulimab, pembrolizumab and carboplatin in lung cancer, run by Shanghai Henlius Biotech, not yet recruiting.","route":"/trials/nct07318883/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07318883","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06335355","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","tldr":"A phase 2/3 trial of adebrelimab, SHR-8068, pemetrexed, carboplatin and other drugs in lung cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, not yet recruiting.","route":"/trials/nct06335355/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06335355","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07076095","name":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by SUNHO（China）BioPharmaceutical CO., Ltd., not yet recruiting.","route":"/trials/nct07076095/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07076095","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07376382","name":"A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","tldr":"A phase 3 trial of SYS6010 and osimertinib in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","route":"/trials/nct07376382/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07376382","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07464327","name":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S","tldr":"A phase 3 trial of HS-20093 and docetaxel in lung cancer, run by Hansoh BioMedical R&D Company, not yet recruiting.","route":"/trials/nct07464327/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07464327","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07816380","name":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Guangzhou JOYO Pharma Co., Ltd, not yet recruiting.","route":"/trials/nct07816380/","status":"planned","kind":"trial","cancerIcon":"ros1-positive-nsclc","sub":"NCT07816380","facets":{"kind":["Trial"],"cancers":["ROS1-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07101627","name":"A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy","tldr":"A phase 2 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","route":"/trials/nct07101627/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07101627","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07809256","name":"A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastati","tldr":"A phase 3 trial in lung cancer, run by EuroCityClinic LLC, now recruiting.","route":"/trials/nct07809256/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07809256","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05085028","name":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung","tldr":"A phase 3 trial in lung cancer, run by Imperial College London, now recruiting.","route":"/trials/nct05085028/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05085028","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06822543","name":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance","tldr":"A phase 2 trial of pembrolizumab, datopotamab deruxtecan and carboplatin in lung cancer, run by Latin American Cooperative Oncology Group, now recruiting.","route":"/trials/nct06822543/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06822543","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06048315","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","tldr":"A phase 3 trial of anlotinib and penpulimab in lung cancer, run by Degan Lu, not yet recruiting.","route":"/trials/nct06048315/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06048315","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07728955","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","tldr":"A phase 3 trial of anlotinib and etoposide in lung cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting.","route":"/trials/nct07728955/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT07728955","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07739199","name":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line","tldr":"A phase 2/3 trial of izalontamab brengitecan, paclitaxel / nab-paclitaxel and carboplatin in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07739199/","status":"planned","kind":"trial","cancerIcon":"lung-squamous-cell-carcinoma","sub":"NCT07739199","facets":{"kind":["Trial"],"cancers":["Squamous cell carcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Squamous cell carcinoma of the lung","href":"/cancers/lung-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05186506","name":"A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by Sichuan University, not yet recruiting.","route":"/trials/nct05186506/","status":"planned","kind":"trial","cancerIcon":"alk-positive-nsclc","sub":"NCT05186506","facets":{"kind":["Trial"],"cancers":["ALK-positive non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07802821","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","tldr":"A phase 3 trial of QLC5508, QL2107, tislelizumab, carboplatin and other drugs in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07802821/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07802821","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07739186","name":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f","tldr":"A phase 2/3 trial of izalontamab brengitecan, tislelizumab, pemetrexed, carboplatin and other drugs in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07739186/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07739186","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07822542","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","tldr":"A phase 3 trial of adebrelimab, cisplatin, carboplatin, pemetrexed and other drugs in lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07822542/","status":"planned","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT07822542","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07831863","name":"A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy","tldr":"A phase 3 trial of docetaxel in lung cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., not yet recruiting.","route":"/trials/nct07831863/","status":"planned","kind":"trial","cancerIcon":"lung-squamous-cell-carcinoma","sub":"NCT07831863","facets":{"kind":["Trial"],"cancers":["Squamous cell carcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Squamous cell carcinoma of the lung","href":"/cancers/lung-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05990127","name":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","tldr":"A phase 3 trial of cadonilimab, tislelizumab, carboplatin, pemetrexed and other drugs in lung cancer, run by Akeso, not yet recruiting.","route":"/trials/nct05990127/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT05990127","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07538271","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","tldr":"A phase 2 trial of benmelstobart, anlotinib and etoposide in lung cancer, run by Yayi He, not yet recruiting.","route":"/trials/nct07538271/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07538271","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07827261","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of izalontamab brengitecan and glecirasib in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07827261/","status":"planned","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT07827261","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07412262","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","tldr":"A phase 2 trial of ivonescimab in lung cancer, run by Guangdong Association of Clinical Trials, now recruiting.","route":"/trials/nct07412262/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07412262","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05859217","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","tldr":"A phase 2 trial of cabozantinib and atezolizumab in lung cancer, run by Jun Zhang, MD, PhD, not yet recruiting.","route":"/trials/nct05859217/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT05859217","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07739966","name":"A Study of DS-3939a in Participants With Solid Tumors","tldr":"A phase 1/2 trial of pembrolizumab, carboplatin and pemetrexed in lung cancer, run by Daiichi Sankyo, not yet recruiting.","route":"/trials/nct07739966/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07739966","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07559929","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","tldr":"A phase 1/2 trial of toripalimab, carboplatin and cisplatin in lung cancer, run by Hangzhou DAC Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct07559929/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07559929","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06526624","name":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","tldr":"A phase 3 trial of HS-20093 in lung cancer, run by Hansoh BioMedical R&D Company, not yet recruiting.","route":"/trials/nct06526624/","status":"planned","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT06526624","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07535437","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of ivonescimab, datopotamab deruxtecan and osimertinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct07535437/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07535437","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07535463","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of ivonescimab in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct07535463/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07535463","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07058519","name":"A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC","tldr":"A phase 2 trial in lung cancer, run by Shanghai Chest Hospital, now recruiting.","route":"/trials/nct07058519/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07058519","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05745740","name":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","tldr":"A phase 1/2 trial of pyrotinib in lung cancer, run by RemeGen Co., Ltd., not yet recruiting.","route":"/trials/nct05745740/","status":"planned","kind":"trial","cancerIcon":"her2-mutant-nsclc","sub":"NCT05745740","facets":{"kind":["Trial"],"cancers":["HER2-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07602855","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","tldr":"A phase 1/2 trial of ivonescimab in lung cancer, run by GlaxoSmithKline, now recruiting.","route":"/trials/nct07602855/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07602855","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06254599","name":"A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","tldr":"A phase 3 trial in lung cancer, run by Shouyao Holdings (Beijing) Co. LTD, not yet recruiting.","route":"/trials/nct06254599/","status":"planned","kind":"trial","cancerIcon":"alk-positive-nsclc","sub":"NCT06254599","facets":{"kind":["Trial"],"cancers":["ALK-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07256509","name":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No","tldr":"A phase 2 trial of SYS6010, osimertinib, pemetrexed, cisplatin and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","route":"/trials/nct07256509/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07256509","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07672223","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","tldr":"A phase 3 trial of SYS6010, tislelizumab, toripalimab, durvalumab and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","route":"/trials/nct07672223/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07672223","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07428044","name":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of trastuzumab deruxtecan in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct07428044/","status":"recruiting","kind":"trial","cancerIcon":"her2-mutant-nsclc","sub":"NCT07428044","facets":{"kind":["Trial"],"cancers":["HER2-mutant non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HER2-mutant non-small-cell lung cancer","href":"/cancers/her2-mutant-nsclc/","tip":"HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06672068","name":"A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC","tldr":"A phase 2 trial of pemetrexed, cisplatin and carboplatin in lung cancer, run by TYK Medicines, Inc, not yet recruiting.","route":"/trials/nct06672068/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06672068","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05607108","name":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","tldr":"A phase 2 trial of ZEN-3694 in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct05607108/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT05607108","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07796100","name":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther","tldr":"A phase 3 trial of carboplatin and lurbinectedin in lung cancer, run by Zai Lab (Shanghai) Co., Ltd., not yet recruiting.","route":"/trials/nct07796100/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07796100","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07821684","name":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc","tldr":"A phase 3 trial of telisotuzumab adizutecan, docetaxel and ramucirumab in lung cancer, run by AbbVie, not yet recruiting.","route":"/trials/nct07821684/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07821684","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07756645","name":"A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan","tldr":"A phase 3 trial of pembrolizumab, carboplatin, paclitaxel / nab-paclitaxel and nab-paclitaxel in lung cancer, run by AbbVie, not yet recruiting.","route":"/trials/nct07756645/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07756645","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06847334","name":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous","tldr":"A phase 3 trial in lung cancer, run by Shanghai Henlius Biotech, not yet recruiting.","route":"/trials/nct06847334/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06847334","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07285148","name":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of osimertinib in lung cancer, run by Beijing Pearl Biotechnology Limited Liability Company, not yet recruiting.","route":"/trials/nct07285148/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07285148","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06284317","name":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Canc","tldr":"A phase 3 trial in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","route":"/trials/nct06284317/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06284317","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06525350","name":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed","tldr":"A phase 2 trial of docetaxel in lung cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., not yet recruiting.","route":"/trials/nct06525350/","status":"planned","kind":"trial","cancerIcon":"met-altered-nsclc","sub":"NCT06525350","facets":{"kind":["Trial"],"cancers":["MET exon 14 and MET-amplified non-small-cell lung cancer","Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."},{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07203053","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","tldr":"A phase 2 trial of tarlatamab in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","route":"/trials/nct07203053/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07203053","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06248606","name":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","tldr":"A phase 2 trial of adagrasib in lung cancer, run by Ryan Gentzler, MD, now recruiting.","route":"/trials/nct06248606/","status":"recruiting","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT06248606","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07746388","name":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","tldr":"A phase 2 trial of cemiplimab in lung cancer, run by University of Maryland, Baltimore, not yet recruiting.","route":"/trials/nct07746388/","status":"planned","kind":"trial","cancerIcon":"pdl1-high-nsclc","sub":"NCT07746388","facets":{"kind":["Trial"],"cancers":["PD-L1-high non-small-cell lung cancer without a driver mutation","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"PD-L1-high non-small-cell lung cancer without a driver mutation","href":"/cancers/pdl1-high-nsclc/","tip":"Lung cancers that carry a lot of PD-L1 and no targetable mutation can be treated with an immunotherapy antibody alone instead of chemotherapy. Pembrolizumab keeps about a third of patients alive at five years, roughly double what chemotherapy achieved, and adding chemotherapy is reserved for those who need a fast response."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06545747","name":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","tldr":"A phase 3 trial in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct06545747/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT06545747","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06616584","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","tldr":"A phase 2/3 trial of cemiplimab, dexamethasone, docetaxel and ramucirumab in lung cancer, run by SWOG Cancer Research Network, now recruiting.","route":"/trials/nct06616584/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06616584","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06141070","name":"Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease","tldr":"A phase 3 trial in lung cancer, run by Vastra Gotaland Region, now recruiting.","route":"/trials/nct06141070/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06141070","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07715396","name":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","tldr":"A phase 3 trial of tislelizumab and pembrolizumab in lung cancer, run by AIO-Studien-gGmbH, not yet recruiting.","route":"/trials/nct07715396/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07715396","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06719336","name":"Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)","tldr":"A phase 3 trial in lung cancer, run by Anhui Shi, MD, not yet recruiting.","route":"/trials/nct06719336/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06719336","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06475209","name":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","tldr":"A phase 2 trial of adebrelimab and rivoceranib (apatinib) in lung cancer, run by Tang-Du Hospital, now recruiting.","route":"/trials/nct06475209/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06475209","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07560358","name":"Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","route":"/trials/nct07560358/","status":"planned","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT07560358","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06672133","name":"Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC","tldr":"A phase 3 trial of adebrelimab in lung cancer, run by Jinming Yu, not yet recruiting.","route":"/trials/nct06672133/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06672133","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07149363","name":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by Alliance Foundation Trials, LLC., now recruiting.","route":"/trials/nct07149363/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07149363","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05825443","name":"Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients","tldr":"A phase 2 trial of camrelizumab in lung cancer, run by Nanfang Hospital, Southern Medical University, now recruiting.","route":"/trials/nct05825443/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT05825443","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07802834","name":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC","tldr":"A phase 2 trial of zipalertinib in lung cancer, run by Stanford University, not yet recruiting.","route":"/trials/nct07802834/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07802834","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04317534","name":"Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","tldr":"A phase 2 trial of pembrolizumab in lung cancer, run by Greg Durm, MD, now recruiting.","route":"/trials/nct04317534/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04317534","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06323148","name":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","tldr":"A phase 3 trial of osimertinib in lung cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct06323148/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06323148","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04772287","name":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","tldr":"A phase 3 trial of toripalimab in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","route":"/trials/nct04772287/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT04772287","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","ALK-positive non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06780839","name":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","tldr":"A phase 2 trial of ensartinib in lung cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.","route":"/trials/nct06780839/","status":"planned","kind":"trial","cancerIcon":"alk-positive-nsclc","sub":"NCT06780839","facets":{"kind":["Trial"],"cancers":["ALK-positive non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07158840","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","tldr":"A phase 2 trial of ivonescimab in lung cancer, run by Akeso, not yet recruiting.","route":"/trials/nct07158840/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07158840","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06043973","name":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","tldr":"A phase 3 trial of aumolertinib in lung cancer, run by Qianfoshan Hospital, now recruiting.","route":"/trials/nct06043973/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06043973","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03637816","name":"Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer","tldr":"A phase 2/3 trial in lung cancer, run by M.D. Anderson Cancer Center, active but no longer recruiting.","route":"/trials/nct03637816/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03637816","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04322617","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","tldr":"A phase 2/3 trial of anlotinib in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.","route":"/trials/nct04322617/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04322617","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07443397","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","tldr":"A phase 3 trial of anlotinib in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct07443397/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07443397","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07160686","name":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","tldr":"A phase 3 trial in lung cancer, run by University of Birmingham, not yet recruiting.","route":"/trials/nct07160686/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07160686","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05800223","name":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer","tldr":"A phase 3 trial of aumolertinib in lung cancer, run by Shanghai Cancer Hospital, China, now recruiting.","route":"/trials/nct05800223/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05800223","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06663098","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","tldr":"A phase 2 trial of atezolizumab, carboplatin and etoposide in lung cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica, now recruiting.","route":"/trials/nct06663098/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06663098","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03977194","name":"Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy","tldr":"A phase 3 trial of carboplatin, paclitaxel / nab-paclitaxel and atezolizumab in lung cancer, run by Intergroupe Francophone de Cancerologie Thoracique, active but no longer recruiting.","route":"/trials/nct03977194/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03977194","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07481786","name":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","tldr":"A phase 3 trial of bevacizumab in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct07481786/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07481786","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07485452","name":"Boosting Osimertinib Blood Brain Barrier Penetration","tldr":"A phase 2 trial in lung cancer, run by Maastricht University Medical Center, now recruiting.","route":"/trials/nct07485452/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07485452","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05393466","name":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","tldr":"A phase 1/2 trial in lung cancer, run by Xcovery Holdings, Inc., not yet recruiting.","route":"/trials/nct05393466/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT05393466","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04933903","name":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","tldr":"A phase 2 trial of ipilimumab and nivolumab in lung cancer, run by Brown University, now recruiting.","route":"/trials/nct04933903/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04933903","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01639508","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","tldr":"A phase 2 trial of cabozantinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct01639508/","status":"recruiting","kind":"trial","cancerIcon":"ros1-positive-nsclc","sub":"NCT01639508","facets":{"kind":["Trial"],"cancers":["ROS1-positive non-small-cell lung cancer","RET fusion-positive non-small-cell lung cancer","NTRK fusion-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."},{"label":"RET fusion-positive non-small-cell lung cancer","href":"/cancers/ret-fusion-nsclc/","tip":"RET fusion lung cancer is a rare adenocarcinoma driven by a fused RET gene. The selective pill selpercatinib shrinks most tumours and more than doubles the time to progression compared with chemotherapy and immunotherapy, and pralsetinib is a second option."},{"label":"NTRK fusion-positive non-small-cell lung cancer","href":"/cancers/ntrk-fusion-nsclc/","tip":"NTRK fusion lung cancer is very rare and is treated with the same TRK-blocking pills approved for any cancer with the fusion: larotrectinib, entrectinib or repotrectinib shrink most tumours, including in the brain, so the point is to test broadly enough to find it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06096844","name":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","tldr":"A phase 3 trial of carboplatin, nab-paclitaxel, paclitaxel / nab-paclitaxel, pembrolizumab and other drugs in lung cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct06096844/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06096844","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07197853","name":"Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective,","tldr":"A phase 3 trial in lung cancer, run by Xin Ye, not yet recruiting.","route":"/trials/nct07197853/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07197853","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06416852","name":"Clinical Study of 18F-Alfatide Injection PET/CT","tldr":"A phase 3 trial in lung cancer, run by Yantai LNC Biotechnology Singapore PTE. LTD., not yet recruiting.","route":"/trials/nct06416852/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06416852","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06828757","name":"Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Hunan Province Tumor Hospital, not yet recruiting.","route":"/trials/nct06828757/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06828757","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06961188","name":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","tldr":"A phase 3 trial in lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct06961188/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06961188","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06632327","name":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","tldr":"A phase 3 trial of cisplatin, carboplatin, pemetrexed, gemcitabine and other drugs in lung cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.","route":"/trials/nct06632327/","status":"active","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06632327","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct01993810","name":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","tldr":"A phase 3 trial of carboplatin, cisplatin, durvalumab, etoposide and other drugs in lung cancer, run by Radiation Therapy Oncology Group, active but no longer recruiting.","route":"/trials/nct01993810/","status":"active","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT01993810","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07554846","name":"Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC","tldr":"A phase 3 trial in lung cancer, run by Fudan University, now recruiting.","route":"/trials/nct07554846/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07554846","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04339218","name":"Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","tldr":"A phase 3 trial of pembrolizumab, pemetrexed and carboplatin in lung cancer, run by Institut Bergonié, now recruiting.","route":"/trials/nct04339218/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT04339218","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06951646","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","tldr":"A phase 2 trial of ivonescimab and docetaxel in lung cancer, run by Second Xiangya Hospital of Central South University, now recruiting.","route":"/trials/nct06951646/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06951646","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07016126","name":"D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC","tldr":"A phase 3 trial in lung cancer, run by Guangdong Provincial People's Hospital, now recruiting.","route":"/trials/nct07016126/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07016126","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07707895","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","tldr":"A phase 1/2 trial of obrixtamig, ZL-1310 and atezolizumab in lung cancer, run by Boehringer Ingelheim, not yet recruiting.","route":"/trials/nct07707895/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT07707895","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05255302","name":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","tldr":"A phase 2/3 trial of pemetrexed in lung cancer, run by Intergroupe Francophone de Cancerologie Thoracique, now recruiting.","route":"/trials/nct05255302/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05255302","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05987644","name":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements","tldr":"A phase 1/2 trial of alectinib in lung cancer, run by Joshua Palmer, now recruiting.","route":"/trials/nct05987644/","status":"recruiting","kind":"trial","cancerIcon":"alk-positive-nsclc","sub":"NCT05987644","facets":{"kind":["Trial"],"cancers":["ALK-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07361484","name":"Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)","tldr":"A phase 3 trial of docetaxel in lung cancer, run by BeyondSpring Pharmaceuticals Inc., not yet recruiting.","route":"/trials/nct07361484/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07361484","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","ALK-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07015892","name":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","tldr":"A phase 3 trial in lung cancer, run by Instituto de Investigación Biomédica de Salamanca, now recruiting.","route":"/trials/nct07015892/","status":"recruiting","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT07015892","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04597671","name":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)","tldr":"A phase 3 trial of durvalumab in lung cancer, run by Association NVALT Studies, active but no longer recruiting.","route":"/trials/nct04597671/","status":"active","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT04597671","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04499053","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","tldr":"A phase 2 trial of durvalumab and tremelimumab in lung cancer, run by Georgetown University, now recruiting.","route":"/trials/nct04499053/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04499053","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04980716","name":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","tldr":"A phase 3 trial in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct04980716/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT04980716","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07251582","name":"Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.","route":"/trials/nct07251582/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07251582","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04536675","name":"Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery","tldr":"A phase 3 trial in lung cancer, run by Samsung Medical Center, active but no longer recruiting.","route":"/trials/nct04536675/","status":"active","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04536675","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06230445","name":"Effects of Digital Therapeutic in Whole Process Management of Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct06230445/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06230445","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05055908","name":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","tldr":"A phase 3 trial of pemetrexed and pembrolizumab in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.","route":"/trials/nct05055908/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT05055908","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06281964","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","tldr":"A phase 3 trial of pemetrexed in lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.","route":"/trials/nct06281964/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06281964","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04762459","name":"Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com","tldr":"A phase 3 trial of aumolertinib, pemetrexed and cisplatin in lung cancer, run by Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct04762459/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT04762459","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04465968","name":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","tldr":"A phase 3 trial of cisplatin and durvalumab in lung cancer, run by National Cancer Center Hospital East, not yet recruiting.","route":"/trials/nct04465968/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04465968","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06698965","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","tldr":"A phase 2 trial of carboplatin and trilaciclib in lung cancer, run by Shanghai Chest Hospital, now recruiting.","route":"/trials/nct06698965/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06698965","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06607796","name":"Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy","tldr":"A phase 3 trial in lung cancer, run by Zhou Chengzhi, now recruiting.","route":"/trials/nct06607796/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06607796","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06319313","name":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","tldr":"A phase 2/3 trial of JMT101, docetaxel and HB1801 in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.","route":"/trials/nct06319313/","status":"planned","kind":"trial","cancerIcon":"lung-squamous-cell-carcinoma","sub":"NCT06319313","facets":{"kind":["Trial"],"cancers":["Squamous cell carcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Squamous cell carcinoma of the lung","href":"/cancers/lung-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06028633","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","tldr":"A phase 2 trial of pembrolizumab, lenvatinib and nab-paclitaxel in lung cancer, run by Peking University First Hospital, not yet recruiting.","route":"/trials/nct06028633/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06028633","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04829708","name":"Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission Aft","tldr":"A phase 3 trial in lung cancer, run by Shandong Cancer Hospital and Institute, now recruiting.","route":"/trials/nct04829708/","status":"recruiting","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT04829708","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05918302","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","tldr":"A phase 3 trial of 177Lu-edotreotide and everolimus in lung cancer, run by Grupo Espanol de Tumores Neuroendocrinos, now recruiting.","route":"/trials/nct05918302/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT05918302","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07545213","name":"Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","tldr":"A phase 2 trial of sacituzumab tirumotecan in lung cancer, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, not yet recruiting.","route":"/trials/nct07545213/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07545213","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07034326","name":"Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","tldr":"A phase 2/3 trial in lung cancer, run by Kong Fanming, now recruiting.","route":"/trials/nct07034326/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07034326","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06810375","name":"Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery","tldr":"A phase 3 trial in lung cancer, run by George Washington University, now recruiting.","route":"/trials/nct06810375/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06810375","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05764928","name":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","tldr":"A phase 1/2 trial in lung cancer, run by Rgene Corporation, not yet recruiting.","route":"/trials/nct05764928/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05764928","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06775483","name":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","tldr":"A phase 2 trial of JSKN016 and docetaxel in lung cancer, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, not yet recruiting.","route":"/trials/nct06775483/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06775483","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06872541","name":"Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas","tldr":"A phase 2/3 trial in lung cancer, run by University of Sao Paulo, active but no longer recruiting.","route":"/trials/nct06872541/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06872541","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06448572","name":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.","tldr":"A phase 1/2 trial in lung cancer, run by University Hospital, Lille, now recruiting.","route":"/trials/nct06448572/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06448572","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05502913","name":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by Soroka University Medical Center, now recruiting.","route":"/trials/nct05502913/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT05502913","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06759857","name":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","tldr":"A phase 3 trial of afatinib in lung cancer, run by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., now recruiting.","route":"/trials/nct06759857/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06759857","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06840782","name":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","tldr":"A phase 3 trial in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","route":"/trials/nct06840782/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06840782","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07355205","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","tldr":"A phase 1/2 trial of ipilimumab, nivolumab and nogapendekin alfa inbakicept in lung cancer, run by Washington University School of Medicine, now recruiting.","route":"/trials/nct07355205/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07355205","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07492342","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","tldr":"A phase 2 trial of fulzerasib in lung cancer, run by Jianxing He, now recruiting.","route":"/trials/nct07492342/","status":"recruiting","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT07492342","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07289646","name":"Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy","tldr":"A phase 3 trial in lung cancer, run by University Hospital, Brest, not yet recruiting.","route":"/trials/nct07289646/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07289646","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06674343","name":"Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations","tldr":"A phase 3 trial of furmonertinib in lung cancer, run by Peking Union Medical College Hospital, now recruiting.","route":"/trials/nct06674343/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06674343","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05334277","name":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","tldr":"A phase 2 trial of furmonertinib, pemetrexed, carboplatin and bevacizumab in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct05334277/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05334277","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07294261","name":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","tldr":"A phase 2 trial in lung cancer, run by Sun Yat-sen University, not yet recruiting.","route":"/trials/nct07294261/","status":"planned","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT07294261","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07554859","name":"GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by Genfleet Therapeutics (Shanghai) Inc., not yet recruiting.","route":"/trials/nct07554859/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07554859","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07718737","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","tldr":"A phase 2/3 trial of AMT-116 and ramucirumab in lung cancer, run by Multitude Therapeutics Inc., not yet recruiting.","route":"/trials/nct07718737/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07718737","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06908772","name":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","tldr":"A phase 2/3 trial in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.","route":"/trials/nct06908772/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06908772","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05852990","name":"Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC","tldr":"A phase 3 trial in lung cancer, run by Instituto Nacional de Cancerologia de Mexico, now recruiting.","route":"/trials/nct05852990/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05852990","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06198907","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","tldr":"A phase 2 trial of golidocitinib and sintilimab in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","route":"/trials/nct06198907/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06198907","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07110103","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","tldr":"A phase 2 trial of golidocitinib in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct07110103/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07110103","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07213375","name":"High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy","tldr":"A phase 2/3 trial of dexamethasone in lung cancer, run by Rigshospitalet, Denmark, now recruiting.","route":"/trials/nct07213375/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07213375","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02448992","name":"Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer","tldr":"A phase 2/3 trial in lung cancer, run by Chang Gung Memorial Hospital, now recruiting.","route":"/trials/nct02448992/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT02448992","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07052669","name":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","tldr":"A phase 3 trial in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct07052669/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT07052669","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07198841","name":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","tldr":"A phase 2 trial of fulzerasib and cetuximab in lung cancer, run by Guangdong Association of Clinical Trials, now recruiting.","route":"/trials/nct07198841/","status":"recruiting","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT07198841","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07402070","name":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of IBI363 in lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., not yet recruiting.","route":"/trials/nct07402070/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07402070","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06840704","name":"Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Hunan Cancer Hospital, now recruiting.","route":"/trials/nct06840704/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT06840704","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06498635","name":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","tldr":"A phase 3 trial of durvalumab in lung cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct06498635/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06498635","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05522660","name":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","route":"/trials/nct05522660/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05522660","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06478108","name":"Interventional Software for Multi-immunotherapy of Solid Tumors","tldr":"A phase 2/3 trial in lung cancer, run by Second Affiliated Hospital of Guangzhou Medical University, now recruiting.","route":"/trials/nct06478108/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06478108","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07718243","name":"Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC","tldr":"A phase 1/2 trial in lung cancer, run by Institute of Cancer Research, United Kingdom, now recruiting.","route":"/trials/nct07718243/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07718243","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04273061","name":"Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","tldr":"A phase 2 trial of atezolizumab in lung cancer, run by British Columbia Cancer Agency, now recruiting.","route":"/trials/nct04273061/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT04273061","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07405190","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","tldr":"A phase 2 trial of ivonescimab, carboplatin and pemetrexed in lung cancer, run by Massachusetts General Hospital, now recruiting.","route":"/trials/nct07405190/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07405190","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06581380","name":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","tldr":"A phase 3 trial of topotecan in lung cancer, run by JenKem Technology Co., Ltd., not yet recruiting.","route":"/trials/nct06581380/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06581380","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06380348","name":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara","tldr":"A phase 3 trial of cisplatin and pemetrexed in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.","route":"/trials/nct06380348/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06380348","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct02468024","name":"JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by University of Texas Southwestern Medical Center, now recruiting.","route":"/trials/nct02468024/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT02468024","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06505837","name":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","tldr":"A phase 3 trial of pemetrexed and toripalimab in lung cancer, run by Shanghai Junshi Bioscience Co., Ltd., active but no longer recruiting.","route":"/trials/nct06505837/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06505837","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07154368","name":"JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.","tldr":"A phase 3 trial of pemetrexed in lung cancer, run by Guangzhou JOYO Pharma Co., Ltd, not yet recruiting.","route":"/trials/nct07154368/","status":"planned","kind":"trial","cancerIcon":"ros1-positive-nsclc","sub":"NCT07154368","facets":{"kind":["Trial"],"cancers":["ROS1-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06858410","name":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma","tldr":"A phase 3 trial of lorlatinib in lung cancer, run by Guangdong Association of Clinical Trials, not yet recruiting.","route":"/trials/nct06858410/","status":"planned","kind":"trial","cancerIcon":"alk-positive-nsclc","sub":"NCT06858410","facets":{"kind":["Trial"],"cancers":["ALK-positive non-small-cell lung cancer","Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."},{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07050043","name":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","tldr":"A phase 3 trial in lung cancer, run by Dr Arvindran A/L Alaga, now recruiting.","route":"/trials/nct07050043/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07050043","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07355231","name":"Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI","tldr":"A phase 1/2 trial in lung cancer, run by Xemed LLC, not yet recruiting.","route":"/trials/nct07355231/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07355231","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07153055","name":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","tldr":"A phase 1/2 trial of lurbinectedin and osimertinib in lung cancer, run by Misty Shields, now recruiting.","route":"/trials/nct07153055/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07153055","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07149649","name":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","tldr":"A phase 2/3 trial in lung cancer, run by Swiss Cancer Institute, now recruiting.","route":"/trials/nct07149649/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07149649","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06419179","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","tldr":"A phase 2 trial of durvalumab and olaparib in lung cancer, run by University of Cologne, now recruiting.","route":"/trials/nct06419179/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT06419179","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05692999","name":"Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study","tldr":"A phase 3 trial in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","route":"/trials/nct05692999/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT05692999","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04841811","name":"MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)","tldr":"A phase 3 trial of aumolertinib in lung cancer, run by Guangdong Association of Clinical Trials, active but no longer recruiting.","route":"/trials/nct04841811/","status":"active","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT04841811","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07477808","name":"Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Hunan Province Tumor Hospital, not yet recruiting.","route":"/trials/nct07477808/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07477808","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05445791","name":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","tldr":"A phase 3 trial in lung cancer, run by Instituto Nacional de Cancerologia de Mexico, now recruiting.","route":"/trials/nct05445791/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05445791","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07723482","name":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","tldr":"A phase 1/2 trial in lung cancer, run by BrYet US, Inc., not yet recruiting.","route":"/trials/nct07723482/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07723482","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05903092","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","tldr":"A phase 2 trial of durvalumab, monalizumab and etoposide in lung cancer, run by Hirva Mamdani, now recruiting.","route":"/trials/nct05903092/","status":"recruiting","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT05903092","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05286957","name":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","tldr":"A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.","route":"/trials/nct05286957/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT05286957","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06610734","name":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext","tldr":"A phase 2 trial of adebrelimab in lung cancer, run by Sichuan University, now recruiting.","route":"/trials/nct06610734/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06610734","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06961201","name":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache","tldr":"A phase 3 trial in lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct06961201/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06961201","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07224152","name":"NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer","tldr":"A phase 1/2 trial of JNJ-90301900 in lung cancer, run by M.D. Anderson Cancer Center, now recruiting.","route":"/trials/nct07224152/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07224152","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07150416","name":"Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study","tldr":"A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Guangzhou Medical University, not yet recruiting.","route":"/trials/nct07150416/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07150416","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06449313","name":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features","tldr":"A phase 2 trial of cemiplimab in lung cancer, run by Georgetown University, now recruiting.","route":"/trials/nct06449313/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT06449313","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06734702","name":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Ca","tldr":"A phase 3 trial in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct06734702/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT06734702","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05469022","name":"Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy","tldr":"A phase 2 trial in lung cancer, run by Konkuk University Medical Center, now recruiting.","route":"/trials/nct05469022/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05469022","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07608159","name":"Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","tldr":"A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","route":"/trials/nct07608159/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07608159","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06987734","name":"Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients","tldr":"A phase 2 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, now recruiting.","route":"/trials/nct06987734/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06987734","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06437977","name":"Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","tldr":"A phase 3 trial of toripalimab in lung cancer, run by Shanghai Chest Hospital, now recruiting.","route":"/trials/nct06437977/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06437977","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05429463","name":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）","tldr":"A phase 3 trial of sintilimab, carboplatin and nab-paclitaxel in lung cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","route":"/trials/nct05429463/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT05429463","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04564157","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","tldr":"A phase 3 trial of carboplatin, paclitaxel / nab-paclitaxel and nivolumab in lung cancer, run by Fundación GECP, active but no longer recruiting.","route":"/trials/nct04564157/","status":"active","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04564157","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05718323","name":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC","tldr":"A phase 2 trial of niraparib in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","route":"/trials/nct05718323/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT05718323","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03391869","name":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of ipilimumab and nivolumab in lung cancer, run by M.D. Anderson Cancer Center, active but no longer recruiting.","route":"/trials/nct03391869/","status":"active","kind":"trial","cancerIcon":"lung-adenocarcinoma","sub":"NCT03391869","facets":{"kind":["Trial"],"cancers":["Adenocarcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Adenocarcinoma of the lung","href":"/cancers/lung-adenocarcinoma/","tip":"Lung adenocarcinoma is the most common type of lung cancer and the form that non-smokers usually get; it starts in the mucus-making gland cells of the small airways, most often at the edge of the lung. It is the type in which testing for a driver mutation matters most, because half of cases have one that a tablet can target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05236946","name":"Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","tldr":"A phase 3 trial in lung cancer, run by Tata Memorial Hospital, now recruiting.","route":"/trials/nct05236946/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05236946","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07008716","name":"Omitting CTV for Primary Tumor in LS-SCLC","tldr":"A phase 3 trial of etoposide, carboplatin and cisplatin in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct07008716/","status":"recruiting","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT07008716","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07001618","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","tldr":"A phase 2 trial of cemiplimab, cisplatin, pemetrexed, bevacizumab and other drugs in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","route":"/trials/nct07001618/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07001618","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07106528","name":"Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer","tldr":"A phase 2/3 trial of topotecan in lung cancer, run by Peking Union Medical College Hospital, not yet recruiting.","route":"/trials/nct07106528/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07106528","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04410796","name":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","tldr":"A phase 2 trial of osimertinib, carboplatin and pemetrexed in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","route":"/trials/nct04410796/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT04410796","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04695925","name":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations","tldr":"A phase 3 trial of osimertinib, pemetrexed and carboplatin in lung cancer, run by Li Zhang, MD, active but no longer recruiting.","route":"/trials/nct04695925/","status":"active","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT04695925","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04335292","name":"Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge","tldr":"A phase 2 trial in lung cancer, run by Mark Vincent, now recruiting.","route":"/trials/nct04335292/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT04335292","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04181060","name":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","tldr":"A phase 3 trial of bevacizumab and osimertinib in lung cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct04181060/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT04181060","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07738172","name":"Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of osimertinib in lung cancer, run by National Taiwan University Hospital, now recruiting.","route":"/trials/nct07738172/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07738172","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06102057","name":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","tldr":"A phase 2 trial in lung cancer, run by TheraOp, now recruiting.","route":"/trials/nct06102057/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT06102057","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07819591","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","tldr":"A phase 2 trial of ivonescimab in lung cancer, run by Shaodong Hong, not yet recruiting.","route":"/trials/nct07819591/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT07819591","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07043907","name":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","tldr":"A phase 2 trial in lung cancer, run by Shenzhen Celconta Life Science Co., Ltd., not yet recruiting.","route":"/trials/nct07043907/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07043907","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03774732","name":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","tldr":"A phase 3 trial of pembrolizumab in lung cancer, run by UNICANCER, active but no longer recruiting.","route":"/trials/nct03774732/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03774732","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04153734","name":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","tldr":"A phase 2 trial of pembrolizumab, carboplatin, pemetrexed and nab-paclitaxel in lung cancer, run by Kobe Minimally Invasive Cancer Center, not yet recruiting.","route":"/trials/nct04153734/","status":"planned","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT04153734","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05623319","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","tldr":"A phase 2 trial of pembrolizumab and olaparib in lung cancer, run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, now recruiting.","route":"/trials/nct05623319/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT05623319","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04547504","name":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","tldr":"A phase 3 trial of pembrolizumab in lung cancer, run by University Hospital, Brest, active but no longer recruiting.","route":"/trials/nct04547504/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT04547504","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04846634","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","tldr":"A phase 2 trial of penpulimab, cisplatin, carboplatin, pemetrexed and other drugs in lung cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct04846634/","status":"planned","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT04846634","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05950139","name":"Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC","tldr":"A phase 1/2 trial in lung cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.","route":"/trials/nct05950139/","status":"recruiting","kind":"trial","cancerIcon":"alk-positive-nsclc","sub":"NCT05950139","facets":{"kind":["Trial"],"cancers":["ALK-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07450183","name":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","tldr":"A phase 2 trial of cemiplimab in lung cancer, run by Henry Ford Health System, not yet recruiting.","route":"/trials/nct07450183/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07450183","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06864624","name":"Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC","tldr":"A phase 2 trial of sunvozertinib in lung cancer, run by Tang-Du Hospital, now recruiting.","route":"/trials/nct06864624/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06864624","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04585490","name":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","tldr":"A phase 3 trial of durvalumab, carboplatin, pemetrexed, paclitaxel / nab-paclitaxel and other drugs in lung cancer, run by Maximilian Diehn, now recruiting.","route":"/trials/nct04585490/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT04585490","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07162883","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","tldr":"A phase 3 trial of QL2107 and pembrolizumab in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07162883/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07162883","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07242274","name":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","tldr":"A phase 3 trial of docetaxel in lung cancer, run by Jemincare, not yet recruiting.","route":"/trials/nct07242274/","status":"planned","kind":"trial","cancerIcon":"kras-g12c-nsclc","sub":"NCT07242274","facets":{"kind":["Trial"],"cancers":["KRAS G12C-mutant non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07063329","name":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","tldr":"A phase 1/2 trial in lung cancer, run by Avistone Pharmaceutical（Ningbo）Co., LTD., not yet recruiting.","route":"/trials/nct07063329/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07063329","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06110572","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","tldr":"A phase 1/2 trial of carboplatin, atezolizumab and etoposide in lung cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting.","route":"/trials/nct06110572/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06110572","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05503888","name":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","tldr":"A phase 1/2 trial of aumolertinib and retlirafusp alfa in lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., not yet recruiting.","route":"/trials/nct05503888/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05503888","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07742956","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab In","tldr":"A phase 2 trial in lung cancer, run by Shanghai Allink Biotherapeutics Co., Ltd., not yet recruiting.","route":"/trials/nct07742956/","status":"planned","kind":"trial","cancerIcon":"lung-squamous-cell-carcinoma","sub":"NCT07742956","facets":{"kind":["Trial"],"cancers":["Squamous cell carcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Squamous cell carcinoma of the lung","href":"/cancers/lung-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07603791","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC","tldr":"A phase 2 trial of carboplatin in lung cancer, run by Shanghai Allink Biotherapeutics Co., Ltd., not yet recruiting.","route":"/trials/nct07603791/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07603791","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07057791","name":"Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by PrECOG, LLC., now recruiting.","route":"/trials/nct07057791/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07057791","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07234877","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","tldr":"A phase 2 trial of ivonescimab, carboplatin, pemetrexed, paclitaxel / nab-paclitaxel and other drugs in lung cancer, run by European Organisation for Research and Treatment of Cancer - EORTC, not yet recruiting.","route":"/trials/nct07234877/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07234877","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06121505","name":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","tldr":"A phase 2 trial of sintilimab in lung cancer, run by Sichuan University, now recruiting.","route":"/trials/nct06121505/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06121505","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07360132","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous","tldr":"A phase 3 trial of carboplatin and paclitaxel / nab-paclitaxel in lung cancer, run by Shanghai Huaota Biopharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07360132/","status":"planned","kind":"trial","cancerIcon":"lung-squamous-cell-carcinoma","sub":"NCT07360132","facets":{"kind":["Trial"],"cancers":["Squamous cell carcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Squamous cell carcinoma of the lung","href":"/cancers/lung-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07383116","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","tldr":"A phase 3 trial of pemetrexed, carboplatin, cisplatin and tislelizumab in lung cancer, run by Shanghai Huaota Biopharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07383116/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07383116","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07754123","name":"Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC","tldr":"A phase 3 trial of cisplatin and carboplatin in lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07754123/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07754123","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07829549","name":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act","tldr":"A phase 3 trial of carboplatin and tislelizumab in lung cancer, run by RemeGen Co., Ltd., not yet recruiting.","route":"/trials/nct07829549/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07829549","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06031558","name":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","tldr":"A phase 3 trial in lung cancer, run by Shouyao Holdings (Beijing) Co. LTD, active but no longer recruiting.","route":"/trials/nct06031558/","status":"active","kind":"trial","cancerIcon":"ret-fusion-nsclc","sub":"NCT06031558","facets":{"kind":["Trial"],"cancers":["RET fusion-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"RET fusion-positive non-small-cell lung cancer","href":"/cancers/ret-fusion-nsclc/","tip":"RET fusion lung cancer is a rare adenocarcinoma driven by a fused RET gene. The selective pill selpercatinib shrinks most tumours and more than doubles the time to progression compared with chemotherapy and immunotherapy, and pralsetinib is a second option."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07416058","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","tldr":"A phase 2 trial of iparomlimab and tuvonralimab in lung cancer, run by Guangdong Association of Clinical Trials, not yet recruiting.","route":"/trials/nct07416058/","status":"planned","kind":"trial","cancerIcon":"lung-adenocarcinoma","sub":"NCT07416058","facets":{"kind":["Trial"],"cancers":["Adenocarcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Adenocarcinoma of the lung","href":"/cancers/lung-adenocarcinoma/","tip":"Lung adenocarcinoma is the most common type of lung cancer and the form that non-smokers usually get; it starts in the mucus-making gland cells of the small airways, most often at the edge of the lung. It is the type in which testing for a driver mutation matters most, because half of cases have one that a tablet can target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06634056","name":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","tldr":"A phase 2 trial in lung cancer, run by University Health Network, Toronto, now recruiting.","route":"/trials/nct06634056/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT06634056","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06784791","name":"Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mut","tldr":"A phase 2 trial of carboplatin and pemetrexed in lung cancer, run by University Hospital, Essen, now recruiting.","route":"/trials/nct06784791/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06784791","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06623656","name":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","tldr":"A phase 2 trial of cemiplimab in lung cancer, run by Weill Medical College of Cornell University, now recruiting.","route":"/trials/nct06623656/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06623656","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07135882","name":"Primary Radiotherapy In MEtastatic Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Trans Tasman Radiation Oncology Group, not yet recruiting.","route":"/trials/nct07135882/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07135882","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06745882","name":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","tldr":"A phase 2 trial of cisplatin, carboplatin, pemetrexed, pembrolizumab and other drugs in lung cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.","route":"/trials/nct06745882/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06745882","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07636226","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","tldr":"A phase 2/3 trial of iparomlimab and tuvonralimab and anlotinib in lung cancer, run by Sun Yat-sen University, not yet recruiting.","route":"/trials/nct07636226/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT07636226","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07453394","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","tldr":"A phase 1/2 trial of bevacizumab, olaparib, iparomlimab and tuvonralimab, QL2107 and other drugs in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","route":"/trials/nct07453394/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07453394","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06814496","name":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","tldr":"A phase 1/2 trial of tarlatamab in lung cancer, run by University of Arizona, now recruiting.","route":"/trials/nct06814496/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06814496","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07808138","name":"RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by The Netherlands Cancer Institute, not yet recruiting.","route":"/trials/nct07808138/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07808138","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06686771","name":"Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Canadian Cancer Trials Group, now recruiting.","route":"/trials/nct06686771/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06686771","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06315010","name":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis","tldr":"A phase 2 trial of repotrectinib in lung cancer, run by MedSIR, now recruiting.","route":"/trials/nct06315010/","status":"recruiting","kind":"trial","cancerIcon":"ros1-positive-nsclc","sub":"NCT06315010","facets":{"kind":["Trial"],"cancers":["ROS1-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"ROS1-positive non-small-cell lung cancer","href":"/cancers/ros1-positive-nsclc/","tip":"ROS1-positive lung cancer is a rare fusion-driven adenocarcinoma treated with a pill. Crizotinib was the first, and the newer drugs repotrectinib and taletrectinib control the disease for about three years, reach the brain and work against the resistance mutation that defeated the older drugs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05632809","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","tldr":"A phase 2 trial of durvalumab in lung cancer, run by M.D. Anderson Cancer Center, now recruiting.","route":"/trials/nct05632809/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT05632809","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07219576","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","tldr":"A phase 1/2 trial of ruxolitinib and retifanlimab in lung cancer, run by University of California, San Diego, now recruiting.","route":"/trials/nct07219576/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07219576","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04155034","name":"S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cel","tldr":"A phase 3 trial in lung cancer, run by SWOG Cancer Research Network, active but no longer recruiting.","route":"/trials/nct04155034/","status":"active","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT04155034","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06401824","name":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","tldr":"A phase 2 trial of bevacizumab in lung cancer, run by Maastricht University Medical Center, now recruiting.","route":"/trials/nct06401824/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06401824","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07501169","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","tldr":"A phase 2 trial of sacituzumab tirumotecan and anlotinib in lung cancer, run by Sichuan University, not yet recruiting.","route":"/trials/nct07501169/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07501169","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07343479","name":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","tldr":"A phase 2 trial of sacituzumab tirumotecan in lung cancer, run by Zhejiang Cancer Hospital, not yet recruiting.","route":"/trials/nct07343479/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07343479","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05717803","name":"Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)","tldr":"A phase 3 trial in lung cancer, run by Fudan University, now recruiting.","route":"/trials/nct05717803/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT05717803","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06634966","name":"Segmentectomy for Solid-dominant Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Fudan University, now recruiting.","route":"/trials/nct06634966/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06634966","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07169903","name":"Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT","tldr":"A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","route":"/trials/nct07169903/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT07169903","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06031246","name":"Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)","tldr":"A phase 3 trial in lung cancer, run by Fudan University, now recruiting.","route":"/trials/nct06031246/","status":"recruiting","kind":"trial","cancerIcon":"lung-adenocarcinoma","sub":"NCT06031246","facets":{"kind":["Trial"],"cancers":["Adenocarcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Adenocarcinoma of the lung","href":"/cancers/lung-adenocarcinoma/","tip":"Lung adenocarcinoma is the most common type of lung cancer and the form that non-smokers usually get; it starts in the mucus-making gland cells of the small airways, most often at the edge of the lung. It is the type in which testing for a driver mutation matters most, because half of cases have one that a tablet can target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07617389","name":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cance","tldr":"A phase 3 trial in lung cancer, run by Wen-zhao ZHONG, not yet recruiting.","route":"/trials/nct07617389/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07617389","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07131319","name":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","tldr":"A phase 2/3 trial in lung cancer, run by Second Affiliated Hospital of Nanchang University, now recruiting.","route":"/trials/nct07131319/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT07131319","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07155200","name":"Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)","tldr":"A phase 1/2 trial of fOLFIRI (5-FU, leucovorin, irinotecan) in lung cancer, run by Washington University School of Medicine, now recruiting.","route":"/trials/nct07155200/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07155200","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07551635","name":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC","tldr":"A phase 2 trial in lung cancer, run by Dana-Farber Cancer Institute, not yet recruiting.","route":"/trials/nct07551635/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT07551635","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05501665","name":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","tldr":"A phase 1/2 trial of carboplatin, fludeoxyglucose F-18 (FDG), nab-paclitaxel, pembrolizumab and other drugs in lung cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting.","route":"/trials/nct05501665/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05501665","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06457906","name":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","tldr":"A phase 3 trial in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","route":"/trials/nct06457906/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT06457906","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05278052","name":"Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC","tldr":"A phase 3 trial in lung cancer, run by Tata Memorial Hospital, now recruiting.","route":"/trials/nct05278052/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05278052","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07076693","name":"Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）","tldr":"A phase 2/3 trial in lung cancer, run by Shanghai Chest Hospital, active but no longer recruiting.","route":"/trials/nct07076693/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT07076693","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06598527","name":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The","tldr":"A phase 3 trial of tislelizumab in lung cancer, run by Yang Hong, now recruiting.","route":"/trials/nct06598527/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06598527","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06523673","name":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","route":"/trials/nct06523673/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06523673","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07132190","name":"Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","tldr":"A phase 2 trial in lung cancer, run by Ayal A. Aizer, MD, now recruiting.","route":"/trials/nct07132190/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07132190","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07016230","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","tldr":"A phase 2 trial of tarlatamab in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","route":"/trials/nct07016230/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT07016230","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05588388","name":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","tldr":"A phase 2 trial of bevacizumab in lung cancer, run by Kamya Sankar, now recruiting.","route":"/trials/nct05588388/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT05588388","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04093167","name":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","tldr":"A phase 2/3 trial of pembrolizumab in lung cancer, run by Canadian Cancer Trials Group, active but no longer recruiting.","route":"/trials/nct04093167/","status":"active","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT04093167","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07680790","name":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C","tldr":"A phase 3 trial of izalontamab brengitecan, osimertinib, pemetrexed, carboplatin and other drugs in lung cancer, run by Bristol-Myers Squibb, not yet recruiting.","route":"/trials/nct07680790/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07680790","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06885840","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","tldr":"A phase 2 trial of MCLA-129 in lung cancer, run by Betta Pharmaceuticals Co., Ltd., not yet recruiting.","route":"/trials/nct06885840/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06885840","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05450965","name":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer","tldr":"A phase 2 trial of onvansertib in lung cancer, run by University of Maryland, Baltimore, now recruiting.","route":"/trials/nct05450965/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT05450965","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07339059","name":"Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","tldr":"A phase 2 trial of sacituzumab govitecan, atezolizumab and durvalumab in lung cancer, run by Bindu R Potugari, now recruiting.","route":"/trials/nct07339059/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07339059","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06704620","name":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can","tldr":"A phase 3 trial of tislelizumab, pemetrexed, carboplatin and cisplatin in lung cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","route":"/trials/nct06704620/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06704620","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06431633","name":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","tldr":"A phase 3 trial of zimberelimab, sacituzumab govitecan, cisplatin and carboplatin in lung cancer, run by Fundación GECP, now recruiting.","route":"/trials/nct06431633/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06431633","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05578326","name":"Study of Trilaciclib and Lurbinectidin","tldr":"A phase 2 trial of trilaciclib and lurbinectedin in lung cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","route":"/trials/nct05578326/","status":"recruiting","kind":"trial","cancerIcon":"sclc","sub":"NCT05578326","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07806773","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by Tubulis GmbH, not yet recruiting.","route":"/trials/nct07806773/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07806773","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06031181","name":"Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)","tldr":"A phase 3 trial in lung cancer, run by Fudan University, now recruiting.","route":"/trials/nct06031181/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06031181","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05623267","name":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","tldr":"A phase 2/3 trial of sugemalimab in lung cancer, run by Sun Yat-sen University, now recruiting.","route":"/trials/nct05623267/","status":"recruiting","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT05623267","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06338683","name":"Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","tldr":"A phase 3 trial in lung cancer, run by Qinghai Red Cross Hospital, now recruiting.","route":"/trials/nct06338683/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06338683","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07322341","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","tldr":"A phase 2 trial of atezolizumab in lung cancer, run by University of Washington, now recruiting.","route":"/trials/nct07322341/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT07322341","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05570825","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of pembrolizumab in lung cancer, run by University of Washington, now recruiting.","route":"/trials/nct05570825/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT05570825","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07662811","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","tldr":"A phase 2/3 trial of carboplatin, nab-paclitaxel and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.","route":"/trials/nct07662811/","status":"planned","kind":"trial","cancerIcon":"lung-squamous-cell-carcinoma","sub":"NCT07662811","facets":{"kind":["Trial"],"cancers":["Squamous cell carcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Squamous cell carcinoma of the lung","href":"/cancers/lung-squamous-cell-carcinoma/","tip":"Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07633873","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","tldr":"A phase 3 trial of tislelizumab, paclitaxel / nab-paclitaxel, cisplatin and carboplatin in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","route":"/trials/nct07633873/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07633873","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07442565","name":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III","tldr":"A phase 3 trial of SYS6010 and docetaxel in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","route":"/trials/nct07442565/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07442565","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07472647","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","tldr":"A phase 1/2 trial of pemetrexed, paclitaxel / nab-paclitaxel, docetaxel, bevacizumab and other drugs in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.","route":"/trials/nct07472647/","status":"planned","kind":"trial","cancerIcon":"sclc","sub":"NCT07472647","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06045767","name":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","tldr":"A phase 2 trial in lung cancer, run by Ari Raphael, not yet recruiting.","route":"/trials/nct06045767/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06045767","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07637513","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","tldr":"A phase 3 trial of tarlatamab and durvalumab in lung cancer, run by PrECOG, LLC., not yet recruiting.","route":"/trials/nct07637513/","status":"planned","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT07637513","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07423585","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","tldr":"A phase 2 trial of tarlatamab in lung cancer, run by Asrar Alahmadi, now recruiting.","route":"/trials/nct07423585/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT07423585","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07323641","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","tldr":"A phase 2 trial of osimertinib and telisotuzumab vedotin in lung cancer, run by Jonsson Comprehensive Cancer Center, now recruiting.","route":"/trials/nct07323641/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07323641","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04919382","name":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","tldr":"A phase 2 trial of atezolizumab and temozolomide in lung cancer, run by Dwight Owen, now recruiting.","route":"/trials/nct04919382/","status":"recruiting","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT04919382","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06908993","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","tldr":"A phase 3 trial of tepotinib, pemetrexed, vinorelbine, docetaxel and other drugs in lung cancer, run by Intergroupe Francophone de Cancerologie Thoracique, now recruiting.","route":"/trials/nct06908993/","status":"recruiting","kind":"trial","cancerIcon":"met-altered-nsclc","sub":"NCT06908993","facets":{"kind":["Trial"],"cancers":["MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04804644","name":"Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of M","tldr":"A phase 3 trial in lung cancer, run by NRG Oncology, active but no longer recruiting.","route":"/trials/nct04804644/","status":"active","kind":"trial","cancerIcon":"sclc","sub":"NCT04804644","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06500455","name":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","tldr":"A phase 3 trial in lung cancer, run by NRG Oncology, active but no longer recruiting.","route":"/trials/nct06500455/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT06500455","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06500481","name":"Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial","tldr":"A phase 3 trial in lung cancer, run by NRG Oncology, now recruiting.","route":"/trials/nct06500481/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06500481","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03811002","name":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun","tldr":"A phase 3 trial of atezolizumab, carboplatin, cisplatin and etoposide in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","route":"/trials/nct03811002/","status":"active","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT03811002","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04267848","name":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","tldr":"A phase 3 trial of carboplatin, cisplatin, gemcitabine, paclitaxel / nab-paclitaxel and other drugs in lung cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct04267848/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04267848","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04092283","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","tldr":"A phase 3 trial of carboplatin, cisplatin, durvalumab, etoposide and other drugs in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","route":"/trials/nct04092283/","status":"active","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT04092283","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06732401","name":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of ceralasertib and durvalumab in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","route":"/trials/nct06732401/","status":"active","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06732401","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05624996","name":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","tldr":"A phase 3 trial of carboplatin, cisplatin, durvalumab, etoposide and other drugs in lung cancer, run by NRG Oncology, now recruiting.","route":"/trials/nct05624996/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT05624996","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04929041","name":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati","tldr":"A phase 2/3 trial of ipilimumab and nivolumab in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","route":"/trials/nct04929041/","status":"active","kind":"trial","cancerIcon":"lung-adenocarcinoma","sub":"NCT04929041","facets":{"kind":["Trial"],"cancers":["Adenocarcinoma of the lung"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Adenocarcinoma of the lung","href":"/cancers/lung-adenocarcinoma/","tip":"Lung adenocarcinoma is the most common type of lung cancer and the form that non-smokers usually get; it starts in the mucus-making gland cells of the small airways, most often at the edge of the lung. It is the type in which testing for a driver mutation matters most, because half of cases have one that a tablet can target."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04214262","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","tldr":"A phase 3 trial of atezolizumab and fludeoxyglucose F-18 (FDG) in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","route":"/trials/nct04214262/","status":"active","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04214262","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07388524","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","tldr":"A phase 3 trial of atezolizumab in lung cancer, run by National Cancer Institute (NCI), now recruiting.","route":"/trials/nct07388524/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07388524","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct03793179","name":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","tldr":"A phase 3 trial of carboplatin, pembrolizumab and pemetrexed in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.","route":"/trials/nct03793179/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT03793179","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05096663","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","tldr":"A phase 2/3 trial of dexamethasone, docetaxel, gemcitabine, pembrolizumab and other drugs in lung cancer, run by SWOG Cancer Research Network, active but no longer recruiting.","route":"/trials/nct05096663/","status":"active","kind":"trial","cancerIcon":"nsclc","sub":"NCT05096663","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07704645","name":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","tldr":"A phase 2 trial of adebrelimab in lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., not yet recruiting.","route":"/trials/nct07704645/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07704645","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05496166","name":"The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc","tldr":"A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","route":"/trials/nct05496166/","status":"planned","kind":"trial","cancerIcon":"limited-stage-sclc","sub":"NCT05496166","facets":{"kind":["Trial"],"cancers":["Limited-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Limited-stage small-cell lung cancer","href":"/cancers/limited-stage-sclc/","tip":"Small-cell lung cancer that is still confined to one side of the chest is treated to cure with chemotherapy and radiotherapy given together. Adding two years of the immunotherapy antibody durvalumab afterwards lengthened median survival from under three years to over four and a half, the first improvement in this disease in decades."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06370416","name":"the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib","tldr":"A phase 2 trial of trilaciclib in lung cancer, run by Henan Cancer Hospital, now recruiting.","route":"/trials/nct06370416/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT06370416","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07146230","name":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","tldr":"A phase 2 trial of durvalumab, monalizumab and oleclumab in lung cancer, run by Montefiore Medical Center, not yet recruiting.","route":"/trials/nct07146230/","status":"planned","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT07146230","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04871412","name":"The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III","tldr":"A phase 3 trial in lung cancer, run by Ottawa Hospital Research Institute, now recruiting.","route":"/trials/nct04871412/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT04871412","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06865339","name":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of cemiplimab and fianlimab in lung cancer, run by Montefiore Medical Center, now recruiting.","route":"/trials/nct06865339/","status":"recruiting","kind":"trial","cancerIcon":"stage-iii-unresectable-nsclc","sub":"NCT06865339","facets":{"kind":["Trial"],"cancers":["Unresectable stage III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Unresectable stage III non-small-cell lung cancer","href":"/cancers/stage-iii-unresectable-nsclc/","tip":"Stage III lung cancer that cannot be removed is treated with chemotherapy and radiotherapy together, aiming at cure. A year of the immunotherapy antibody durvalumab afterwards raised five-year survival from a third to over 40 percent, and for EGFR-mutated tumours osimertinib after chemoradiation holds the disease for years."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06290869","name":"Tobacco Education and Lung Health Study (TEAL)","tldr":"A phase 3 trial in lung cancer, run by Georgetown University, now recruiting.","route":"/trials/nct06290869/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06290869","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04691817","name":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T","tldr":"A phase 1/2 trial of atezolizumab and tocilizumab in lung cancer, run by Abramson Cancer Center at Penn Medicine, now recruiting.","route":"/trials/nct04691817/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04691817","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06441344","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","tldr":"A phase 3 trial of toripalimab and anlotinib in lung cancer, run by Taizhou Hospital, not yet recruiting.","route":"/trials/nct06441344/","status":"planned","kind":"trial","cancerIcon":"extensive-stage-sclc","sub":"NCT06441344","facets":{"kind":["Trial"],"cancers":["Extensive-stage small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07819578","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","tldr":"A phase 2 trial of toripalimab and sacituzumab tirumotecan in lung cancer, run by Shaodong Hong, not yet recruiting.","route":"/trials/nct07819578/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT07819578","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06951399","name":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of pembrolizumab in lung cancer, run by Rabin Medical Center, not yet recruiting.","route":"/trials/nct06951399/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06951399","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","ALK-positive non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06456138","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","tldr":"A phase 1/2 trial of trametinib, anlotinib and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.","route":"/trials/nct06456138/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06456138","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04875585","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","tldr":"A phase 2 trial of pembrolizumab and lenvatinib in lung cancer, run by Medical University Innsbruck, now recruiting.","route":"/trials/nct04875585/","status":"recruiting","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT04875585","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06851663","name":"Trop2-targeted immunoPET Imaging of Solid Tumors","tldr":"A phase 2/3 trial in lung cancer, run by RenJi Hospital, now recruiting.","route":"/trials/nct06851663/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06851663","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06955325","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","tldr":"A phase 3 trial of icotinib, ensartinib and benmelstobart in lung cancer, run by The First Affiliated Hospital of Guangzhou Medical University, not yet recruiting.","route":"/trials/nct06955325/","status":"planned","kind":"trial","cancerIcon":"resectable-nsclc","sub":"NCT06955325","facets":{"kind":["Trial"],"cancers":["Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct04966663","name":"Using ctDNA to Determine Therapies for Lung Cancer","tldr":"A phase 2 trial of nivolumab, pemetrexed, gemcitabine, cisplatin and other drugs in lung cancer, run by University Health Network, Toronto, now recruiting.","route":"/trials/nct04966663/","status":"recruiting","kind":"trial","cancerIcon":"nsclc","sub":"NCT04966663","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06683703","name":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","tldr":"A phase 2 trial of utidelone and bevacizumab in lung cancer, run by Beijing Biostar Pharmaceuticals Co., Ltd., not yet recruiting.","route":"/trials/nct06683703/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT06683703","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07655622","name":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","tldr":"A phase 1/2 trial of vebreltinib in lung cancer, run by Second Affiliated Hospital of Nanchang University, now recruiting.","route":"/trials/nct07655622/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07655622","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06970782","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","tldr":"A phase 3 trial of vebreltinib and pemetrexed in lung cancer, run by Avistone Biotechnology Co., Ltd., not yet recruiting.","route":"/trials/nct06970782/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06970782","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","MET exon 14 and MET-amplified non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"MET exon 14 and MET-amplified non-small-cell lung cancer","href":"/cancers/met-altered-nsclc/","tip":"MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06127654","name":"Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy","tldr":"A phase 3 trial in lung cancer, run by University of Sydney, now recruiting.","route":"/trials/nct06127654/","status":"recruiting","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06127654","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06102161","name":"Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","tldr":"A phase 3 trial in lung cancer, run by Fudan University, not yet recruiting.","route":"/trials/nct06102161/","status":"planned","kind":"trial","cancerIcon":"lung-cancer","sub":"NCT06102161","facets":{"kind":["Trial"],"cancers":["Lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell (about 85 percent) and small-cell (about 15 percent) disease, which behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct06222489","name":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","tldr":"A phase 2 trial in lung cancer, run by The Netherlands Cancer Institute, now recruiting.","route":"/trials/nct06222489/","status":"recruiting","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT06222489","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07688577","name":"XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors","tldr":"A phase 1/2 trial in lung cancer, run by Xilio Development, Inc., not yet recruiting.","route":"/trials/nct07688577/","status":"planned","kind":"trial","cancerIcon":"nsclc","sub":"NCT07688577","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct05767892","name":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","tldr":"A phase 3 trial of pemetrexed, carboplatin and cisplatin in lung cancer, run by Suzhou Puhe Pharmaceutical Technology Co., LTD, not yet recruiting.","route":"/trials/nct05767892/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT05767892","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07229339","name":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","tldr":"A phase 2 trial of carboplatin, pemetrexed and zipalertinib in lung cancer, run by Jonsson Comprehensive Cancer Center, not yet recruiting.","route":"/trials/nct07229339/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07229339","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer","Resectable stage I to III non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."},{"label":"Resectable stage I to III non-small-cell lung cancer","href":"/cancers/resectable-nsclc/","tip":"Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nct07551414","name":"Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI","tldr":"A phase 2 trial in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","route":"/trials/nct07551414/","status":"planned","kind":"trial","cancerIcon":"egfr-mutant-nsclc","sub":"NCT07551414","facets":{"kind":["Trial"],"cancers":["EGFR-mutated non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"tags":[]},"sortKeys":{"year":0}}]